vs
Clear Channel Outdoor Holdings, Inc.（CCO）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Clear Channel Outdoor Holdings, Inc.的1.7倍（$772.1M vs $461.5M），Revvity净利率更高（12.7% vs 1.7%，领先11.0%），Clear Channel Outdoor Holdings, Inc.同比增速更快（8.2% vs 5.9%），Revvity自由现金流更多（$161.8M vs $30.3M），过去两年Clear Channel Outdoor Holdings, Inc.的营收复合增速更高（18.8% vs 9.0%）
Clear Channel Outdoor Holdings, Inc.是一家专注于户外广告业务的跨国企业，总部位于美国得克萨斯州圣安东尼奥，在全球多个市场布局户外广告媒体网络，为各类品牌客户提供场景化的户外广告传播服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
CCO vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.7倍
$461.5M
营收增速更快
CCO
高出2.3%
5.9%
净利率更高
RVTY
高出11.0%
1.7%
自由现金流更多
RVTY
多$131.5M
$30.3M
两年增速更快
CCO
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $461.5M | $772.1M |
| 净利润 | $8.0M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 23.3% | 14.5% |
| 净利率 | 1.7% | 12.7% |
| 营收同比 | 8.2% | 5.9% |
| 净利润同比 | 144.8% | 3.9% |
| 每股收益（稀释后） | $0.01 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CCORVTY
| Q4 25 | $461.5M | $772.1M | ||
| Q3 25 | $405.6M | $698.9M | ||
| Q2 25 | $402.8M | $720.3M | ||
| Q1 25 | $334.2M | $664.8M | ||
| Q4 24 | $426.7M | $729.4M | ||
| Q3 24 | $375.2M | $684.0M | ||
| Q2 24 | $376.5M | $691.7M | ||
| Q1 24 | $326.8M | $649.9M |
净利润CCORVTY
| Q4 25 | $8.0M | $98.4M | ||
| Q3 25 | $-60.1M | $46.7M | ||
| Q2 25 | $9.5M | $53.9M | ||
| Q1 25 | $62.5M | $42.2M | ||
| Q4 24 | $-17.9M | $94.6M | ||
| Q3 24 | $-32.5M | $94.4M | ||
| Q2 24 | $-39.2M | $55.4M | ||
| Q1 24 | $-89.7M | $26.0M |
毛利率CCORVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率CCORVTY
| Q4 25 | 23.3% | 14.5% | ||
| Q3 25 | 19.9% | 11.7% | ||
| Q2 25 | 19.2% | 12.6% | ||
| Q1 25 | 13.5% | 10.9% | ||
| Q4 24 | 23.5% | 16.3% | ||
| Q3 24 | 17.8% | 14.3% | ||
| Q2 24 | 18.2% | 12.4% | ||
| Q1 24 | 13.4% | 6.8% |
净利率CCORVTY
| Q4 25 | 1.7% | 12.7% | ||
| Q3 25 | -14.8% | 6.7% | ||
| Q2 25 | 2.4% | 7.5% | ||
| Q1 25 | 18.7% | 6.4% | ||
| Q4 24 | -4.2% | 13.0% | ||
| Q3 24 | -8.7% | 13.8% | ||
| Q2 24 | -10.4% | 8.0% | ||
| Q1 24 | -27.4% | 4.0% |
每股收益（稀释后）CCORVTY
| Q4 25 | $0.01 | $0.86 | ||
| Q3 25 | $-0.12 | $0.40 | ||
| Q2 25 | $0.02 | $0.46 | ||
| Q1 25 | $0.13 | $0.35 | ||
| Q4 24 | $-0.03 | $0.77 | ||
| Q3 24 | $-0.07 | $0.77 | ||
| Q2 24 | $-0.08 | $0.45 | ||
| Q1 24 | $-0.19 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $190.0M | $919.9M |
| 总债务越低越好 | $5.1B | — |
| 股东权益账面价值 | $-3.4B | $7.3B |
| 总资产 | $3.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CCORVTY
| Q4 25 | $190.0M | $919.9M | ||
| Q3 25 | $155.0M | $931.4M | ||
| Q2 25 | $138.6M | $991.8M | ||
| Q1 25 | $395.8M | $1.1B | ||
| Q4 24 | $109.7M | $1.2B | ||
| Q3 24 | $201.1M | $1.2B | ||
| Q2 24 | $189.3M | $2.0B | ||
| Q1 24 | $193.2M | $1.7B |
总债务CCORVTY
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.1B | — | ||
| Q2 25 | $5.1B | — | ||
| Q1 25 | $5.3B | — | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $5.7B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
股东权益CCORVTY
| Q4 25 | $-3.4B | $7.3B | ||
| Q3 25 | $-3.5B | $7.4B | ||
| Q2 25 | $-3.4B | $7.6B | ||
| Q1 25 | $-3.4B | $7.6B | ||
| Q4 24 | $-3.6B | $7.7B | ||
| Q3 24 | $-3.6B | $7.9B | ||
| Q2 24 | $-3.6B | $7.9B | ||
| Q1 24 | $-3.5B | $7.8B |
总资产CCORVTY
| Q4 25 | $3.8B | $12.2B | ||
| Q3 25 | $3.8B | $12.1B | ||
| Q2 25 | $3.8B | $12.4B | ||
| Q1 25 | $4.0B | $12.4B | ||
| Q4 24 | $4.8B | $12.4B | ||
| Q3 24 | $4.6B | $12.8B | ||
| Q2 24 | $4.5B | $13.4B | ||
| Q1 24 | $4.6B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $56.3M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $30.3M | $161.8M |
| 自由现金流率自由现金流/营收 | 6.6% | 21.0% |
| 资本支出强度资本支出/营收 | 5.6% | 2.6% |
| 现金转化率经营现金流/净利润 | 7.04× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $32.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流CCORVTY
| Q4 25 | $56.3M | $182.0M | ||
| Q3 25 | $56.2M | $138.5M | ||
| Q2 25 | $-12.6M | $134.3M | ||
| Q1 25 | $14.9M | $128.2M | ||
| Q4 24 | $29.3M | $174.2M | ||
| Q3 24 | $54.5M | $147.9M | ||
| Q2 24 | $30.8M | $158.6M | ||
| Q1 24 | $-34.8M | $147.6M |
自由现金流CCORVTY
| Q4 25 | $30.3M | $161.8M | ||
| Q3 25 | $41.4M | $120.0M | ||
| Q2 25 | $-29.2M | $115.5M | ||
| Q1 25 | $-10.6M | $112.2M | ||
| Q4 24 | $-27.8M | $149.8M | ||
| Q3 24 | $21.0M | $125.6M | ||
| Q2 24 | $5.2M | $136.6M | ||
| Q1 24 | $-61.0M | $129.7M |
自由现金流率CCORVTY
| Q4 25 | 6.6% | 21.0% | ||
| Q3 25 | 10.2% | 17.2% | ||
| Q2 25 | -7.2% | 16.0% | ||
| Q1 25 | -3.2% | 16.9% | ||
| Q4 24 | -6.5% | 20.5% | ||
| Q3 24 | 5.6% | 18.4% | ||
| Q2 24 | 1.4% | 19.7% | ||
| Q1 24 | -18.7% | 20.0% |
资本支出强度CCORVTY
| Q4 25 | 5.6% | 2.6% | ||
| Q3 25 | 3.7% | 2.6% | ||
| Q2 25 | 4.1% | 2.6% | ||
| Q1 25 | 7.6% | 2.4% | ||
| Q4 24 | 13.4% | 3.4% | ||
| Q3 24 | 8.9% | 3.3% | ||
| Q2 24 | 6.8% | 3.2% | ||
| Q1 24 | 8.0% | 2.7% |
现金转化率CCORVTY
| Q4 25 | 7.04× | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | -1.32× | 2.49× | ||
| Q1 25 | 0.24× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CCO
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
